1Schnitzler MA, Lowell JA, Hardinger KL, et al. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant, 2003, 3: 445-451.
2Geddes CC, Church CC, Collidge T, et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant, 2003, 18: 1891-1898.
3Rubin RH, Ikonen T, Gummet JF, et al. The therapeutic of the organ transplant recipient: the linkage of Immunosuppression and antimicrobial strategies. Transpt Infect Dis, 1999, 1: 29.
4Couchoud C, Cucherat M, Haugh M, et al. Cytomegalovirus prophylaxis with antiviral agents is solid organ transplantation.Transplantation, 1998, 65: 641-647.
5Vilacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpt Infect Dis, 1999, 1: 50.
6Schnitzler MA. Costs and consequences of cytomegalovirus disease. Am J Health Syst Pharm, 2003, 60: 5-8.
7Murray BM, Subramaniam S. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.Transpl Infect Dis, 2004, 6: 3-9.
8Sagedal S, Nordal XP, Hartmann A. Pre-emptive therpy of CMVpp65 antigen positiverenal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant, 2003, 18: 1899-1908.
9Dickenmann MJ, Kabulbayev K, Steiger J, et al. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Clin Microbiol Infect, 2004, 10: 337-339.
10Melgosa Hijosa M, Garcia Meseguer C, Pena Garcia P, et al.Preemptive treatment with oral ganciclovir for pediatric renal transplantation. Clin Nephrol, 2004, 61: 246-252.
